Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.
P/E ratio for Zomedica Corp. (ZOM)
P/E ratio as of 2024: -5.68
According to Zomedica Corp.'s latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -5.68. At the end of 2023 the company had a P/E ratio of -9.39.
P/E ratio history for Zomedica Corp. from 2013 to 2024
PE ratio at the end of each year
| Year | P/E ratio |
|---|---|
| 2024 | -5.68 |
| 2023 | -9.39 |
| 2022 | -15.95 |
| 2021 | -4.97 |
| 2020 | -1.78 |
| 2019 | -6.83 |
| 2018 | -21.43 |
| 2017 | -13.75 |
| 2016 | -16.81 |
| 2015 | -19.55 |
| 2014 | -3.61 |
| 2013 | 0.00 |